JP2010540618A - 幼児の成長および発達を増大するための内在性カンナビノイド - Google Patents

幼児の成長および発達を増大するための内在性カンナビノイド Download PDF

Info

Publication number
JP2010540618A
JP2010540618A JP2010527596A JP2010527596A JP2010540618A JP 2010540618 A JP2010540618 A JP 2010540618A JP 2010527596 A JP2010527596 A JP 2010527596A JP 2010527596 A JP2010527596 A JP 2010527596A JP 2010540618 A JP2010540618 A JP 2010540618A
Authority
JP
Japan
Prior art keywords
infant
growth
development
promoting
endogenous cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010527596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540618A5 (enExample
Inventor
エスター フリード
デイビッド ブランスキー，
シモン ベン−シャバト，
Original Assignee
アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド
ベン グリオン ユニバーシティー オブ ザ ネゲフ リサーチ アンド デベロップメント オーソリティー
ハダシト メディカル リサーチ サービシーズ アンド デベロップメント リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド, ベン グリオン ユニバーシティー オブ ザ ネゲフ リサーチ アンド デベロップメント オーソリティー, ハダシト メディカル リサーチ サービシーズ アンド デベロップメント リミテッド filed Critical アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド
Publication of JP2010540618A publication Critical patent/JP2010540618A/ja
Publication of JP2010540618A5 publication Critical patent/JP2010540618A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Pediatric Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010527596A 2007-10-02 2008-10-02 幼児の成長および発達を増大するための内在性カンナビノイド Pending JP2010540618A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96051207P 2007-10-02 2007-10-02
PCT/IL2008/001314 WO2009044402A1 (en) 2007-10-02 2008-10-02 Endocannabinoids for enhancing growth and development in infants

Publications (2)

Publication Number Publication Date
JP2010540618A true JP2010540618A (ja) 2010-12-24
JP2010540618A5 JP2010540618A5 (enExample) 2011-11-24

Family

ID=40239593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010527596A Pending JP2010540618A (ja) 2007-10-02 2008-10-02 幼児の成長および発達を増大するための内在性カンナビノイド

Country Status (5)

Country Link
US (1) US20110172305A1 (enExample)
EP (1) EP2205240A1 (enExample)
JP (1) JP2010540618A (enExample)
CN (1) CN101998855A (enExample)
WO (1) WO2009044402A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220071922A1 (en) * 2018-12-26 2022-03-10 Clear Lake Research, Llc Delivery of health benefits through component formulation
CN111202767A (zh) * 2019-09-04 2020-05-29 汉义生物科技（北京）有限公司 大麻全草提取物在改善tau蛋白和β-淀粉样蛋白病理损伤中应用
CN114748429A (zh) 2020-12-29 2022-07-15 汉义生物科技（北京）有限公司 一种水溶性大麻素制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065997A1 (en) * 2001-02-21 2002-08-29 Unilever Plc Antiperspirant or deodorant compositions
JP2005511632A (ja) * 2001-11-23 2005-04-28 アストラゼネカ・アクチエボラーグ 胃食道逆流疾患の治療のための新しい使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4925673A (en) * 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
EP1292288B1 (en) * 2000-06-23 2004-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
US6913778B2 (en) * 2001-12-21 2005-07-05 Wyeth Infant formula compositions comprising increased amounts of alpha-lactalbumin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065997A1 (en) * 2001-02-21 2002-08-29 Unilever Plc Antiperspirant or deodorant compositions
JP2005511632A (ja) * 2001-11-23 2005-04-28 アストラゼネカ・アクチエボラーグ 胃食道逆流疾患の治療のための新しい使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5010014002; Ｆｒｉｄｅ　Ｅ: 'Ｅｎｄｏｃａｎｎａｂｉｎｏｉｄｓ　ｉｎ　ｔｈｅ　ｃｅｎｔｒａｌ　ｎｅｒｖｏｕｓ　ｓｙｓｔｅｍ--ａｎ　ｏｖｅｒｖｉｅｗ．' Ｐｒｏｓｔａｇｌａｎｄｉｎｓ　Ｌｅｕｋｏｔ　Ｅｓｓｅｎｔ　Ｆａｔｔｙ　Ａｃｉｄｓ Ｖｏｌ．６６　Ｎｏ．２-３, 200202, ｐｐ．２２１-２３３ *
JPN5010014005; Ｆｒｉｄｅ　Ｅ: 'Ｃａｎｎａｂｉｎｏｉｄｓ　ａｎｄ　Ｆｅｅｄｉｎｇ：　Ｔｈｅ　Ｒｏｌｅ　ｏｆ　ｔｈｅ　Ｅｎｄｏｇｅｎｏｕｓ　Ｃａｎｎａｂｉｎｏｉｄ　Ｓｙｓｔｅｍ　ａｓ　ａ　Ｔｒｉｇｇｅｒ　ｆｏｒ　Ｎｅｗｂｏｒｎ　Ｓｕｃ' Ｊ　Ｃａｎｎａｂｉｓ　Ｔｈｅｒ Ｖｏｌ．２　Ｎｏ．３-４, 2002, ｐｐ．５１-６２ *
JPN6013022672; Ｆｒｉｄｅ　Ｅ　ｅｔ　ａｌ．: 'Ｃｒｉｔｉｃａｌ　ｒｏｌｅ　ｏｆ　ｔｈｅ　ｅｎｄｏｇｅｎｏｕｓ　ｃａｎｎａｂｉｎｏｉｄ　ｓｙｓｔｅｍ　ｉｎ　ｍｏｕｓｅ　ｐｕｐ　ｓｕｃｋｌｉｎｇ　ａｎｄ　ｇｒｏｗｔｈ．' Ｅｕｒ　Ｊ　Ｐｈａｒｍａｃｏｌ． Ｖｏｌ．４１９　Ｎｏ．２-３, 20010511, ｐｐ．２０７-２１４ *

Also Published As

Publication number Publication date
EP2205240A1 (en) 2010-07-14
CN101998855A (zh) 2011-03-30
US20110172305A1 (en) 2011-07-14
WO2009044402A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
TWI407963B (zh) Contains the composition of riboflavin and sesamin
JP5584937B2 (ja) ステビア抽出物またはステビア抽出物構成物質を含有する新規な栄養補給食品組成物およびその使用
TWI565420B (zh) 使用β－羥基－β－甲基丁酸鹽改善腦部發育及認知功能的方法
EP1378236B1 (en) Agents against stress-induced diseases
KR20100074190A (ko) 세사민류와 비타민 ｂ１ 류를 배합한 조성물
JP2012527224A (ja) オピオイド受容体刺激化合物（チモキノン、ニゲラ・サティバ）及び食物アレルギー
JP2010540618A (ja) 幼児の成長および発達を増大するための内在性カンナビノイド
EP1604671A1 (en) Muscle-building agent and preventive or remedy for muscle weakening
AU2018272156B2 (en) A nutritional composition for use to enhance attention and/or reduce impulsivity
Gullberg et al. Effects of postnatal caffeine exposure through dam's milk upon weanling rats
JP2019142940A (ja) 桂皮アルデヒド及び亜鉛を含む組成物並びにかかる組成物の使用方法
JP2021078397A (ja) 脂質減少促進剤
JP2007070343A (ja) 睡眠誘導剤、ストレス性不眠症改善剤
JP5110683B2 (ja) 睡眠誘導剤、ストレス性不眠症改善剤
JP2007230954A (ja) 睡眠誘導剤及びストレス性不眠症改善剤
JP2008056628A (ja) 睡眠誘導剤、ストレス性不眠症改善剤
JP2015218119A (ja) 睡眠改善剤及びそれを用いた飲食品
ZA200603227B (en) Veterinary method for administering a vitamin E derivative and formulation
JP2024098986A (ja) 生活活動量の維持、低下予防、低下抑制又は改善用組成物
Ralli et al. The effects in rats of vitamin B12, with and without ethyl alcohol, on nitrogen balance, serum albumin, liver nitrogen and fat
Striepeke et al. In vitro stability of sapropterin dihydrochloride from crushed tablets mixed in applesauce, pudding, and infant formula
JP2008546834A (ja) セレンの豊富な食品の生産用の非経口投与セレノメチオニン
JP2009073747A (ja) アラキドン酸を有効成分とする抗疲労剤
JP2006182760A (ja) １型糖尿病用人乳類似油脂組成物、１型糖尿病用育児用粉乳、１型糖尿病乳幼児用栄養組成物、１型糖尿病用経管栄養組成物、および、１型糖尿病用食
JP2008105977A (ja) 抗不安剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130813

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130913

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140221